Skip to main content

Table 3 Descriptive comparison of mean daily treatment costs per patient for active treatment during the 12 months after the index event in CHF

From: Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective

 

Mean (SD)

95%-CI

Minimum

Maximum

Etanercept (n = 233)

    

Outpatient care

4 (11)

3-6

0

164

Medications

83 (20)

80-86

62

301

Laboratory tests

2 (2)

2-2

0

18

Ambulatory care in hospitals

1 (3)

1-1

0

18

Devices and aids

0 (1)

0-0

0

5

Other claims

2 (7)

1-3

0

95

Total daily cost (etanercept)

92 (26)

89-96

69

328

Adalimumab (n = 201)

    

Outpatient care

4 (4)

4-5

0

22

Medications

84 (12)

82-86

65

159

Laboratory tests

2 (2)

2-2

0

21

Ambulatory care in hospitals

1 (3)

1-2

0

17

Devices and aids

0 (1)

0-0

0

11

Other claims

1 (3)

1-2

0

29

Total daily cost (adalimumab)

93 (14)

91-95

68

169

Infliximab (n = 121)

    

Outpatient care

4 (5)

3-4

0

25

Medications

118 (84)

103-133

36

823

Laboratory tests

3 (3)

3-4

0

17

Ambulatory care in hospitals

9 (9)

7-10

0

65

Devices and aids

1 (1)

0-1

0

4

Other claims

1 (2)

0-1

0

12

Total daily cost (infliximab)

135 (88)

119-151

63

878